buy

BeiGene Ltd ADR buy marge

BeiGene Ltd ADR

Start price

€126.51

/ 50%

Target price

02.01.19

Performance (%)

End price

€126.51

Summary

This prediction ended on with a price of €126.51. marge's BUY prediction for BeiGene Ltd ADR closed unchanged from the start price. marge has 50% into this prediction

Performance without dividends (%)

Name	1w	1m	1y	3y
BeiGene Ltd ADR
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by marge for this prediction

In the thread Beigene Ltd ADR diskutieren

Prediction Buy

Perf. (%)

Target price 198.440

Change

Ends at

BeiGene is a Buy, as the stock is currently over 25% off its high!

The firm possessed a deep, underappreciated pipeline of promising drug candidates.

Management appeared to be progressing their lead products in an efficient and expeditious manner, with promising phase 1 data presented in June for anti-PD-1 antibody BGB-A317 in combination with their PARP inhibitor BGB-290 in patients with solid tumors. Updated data from an early study of BTK inhibitor BGB-3111 in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was also quite promising (overall response rate of 94% with very low discontinuation rate of 3%).

Validation came in the form of a global collaboration deal signed with Celgene to commercialize PD-1 inhibitor BGB-A137. The specifics of the deal were interesting, with BeiGene management wisely

retaining exclusive rights in Asia (except Japan) as well as receiving Celgene's commercial operations in China (exclusive license to commercialize Abraxane, Vidaza and Revlimid). BeiGene also received
licensing rights in China to Celgene's next generation CelMod for lymphoma and hepatocellular carcinoma, CC-122. The financial terms were very generous, with BeiGene to receive upfront licensing fees of $263 million. The larger firm purchased 32.7 million shares at $59.55 per ADS (a 35% premium over the 11-day volume-weighted average price at the time).